Differences in Ventricle Dilation and Clinical Findings between the Early- and Late-Onset Subtypes of Alzheimer's Dementia.

Kono, Kazuhiko; Yamamoto, Takayuki; Kuzuya, Fumio; Endo, Hideki

doi:10.3143/geriatrics.28.358

Cited by 3 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45,46 However, amyloid β-injected rabbits did not demonstrate these volumetric changes within 25 days, 34 but after 60 days, these rabbits demonstrated significant volumetric changes in the temporal lobe and lateral ventricles. 37 In this study, Al-M-treated aged New Zealand rabbit showed significant volumetric changes in the 47 The robust studies and findings in humans have demonstrated temporal lobe atrophy and ventricular dilatation, [13][14][15][19][20][21][22][23][24][25][26][27][28][29][30] but they have failed to streamline substantial therapeutic strategies to either stop or slow down the progression of AD. Our recent studies on animal models have highlighted the role of animal models and molecular-level studies in AD pathology.…”

Section: Discussionmentioning

confidence: 98%

“…The robust studies and findings in humans have demonstrated temporal lobe atrophy and ventricular dilatation, , but they have failed to streamline substantial therapeutic strategies to either stop or slow down the progression of AD. Our recent studies on animal models have highlighted the role of animal models and molecular‐level studies in AD pathology .…”

Section: Discussionmentioning

confidence: 99%

“…Dilatation of ventricles is a prominent pathological feature . Further ventricular volume change also gives necessary evidence in neurocognitive testing by providing adequate information about the mechanisms of disease‐modifying therapies .…”

Section: Introductionmentioning

confidence: 99%

“…18 Dilatation of ventricles is a prominent pathological feature. [19][20][21][22][23][24][25][26][27][28][29][30] Further ventricular volume change also gives necessary evidence in neurocognitive testing by providing adequate information about the mecha-nisms of disease-modifying therapies. 31 A wealth of studies has substantiated the fact that memory impairment is directly proportional to the atrophy of the medial temporal lobe in both healthy ageing and AD subjects.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

First magenetic resonance imaging studies on aluminium maltolate‐treated aged New Zealand rabbits: an Alzheimer's animal model

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

First magenetic resonance imaging studies on aluminium maltolate‐treated aged New Zealand rabbits: an Alzheimer's animal model

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Early brain volume involution in neurodegenerative diseases, as a measure of brain atrophy, can be considered as a potential predictor for cognitive impairment. Moreover, on the basis of the third ventricle or midbrain area ( 14 , 15 ) differentiation between different forms of dementia are made.…”

Section: Introductionmentioning

confidence: 99%

Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis

et al. 2022

View full text Add to dashboard Cite

BackgroundDespite antiretroviral therapy, cognitive dysfunction seems to remain a major issue for people living with human immunodeficiency virus (PLWH). Previous studies showed a correlation between the width of the third ventricle (WTV) and neurocognitive disorders in PLWH.Patients and methodsWe investigated prevalence and correlation of neuropsychological disorders using WTV as a brain atrophy marker examined by transcranial sonography and MRI in PLWH and healthy age- and gender-matched controls. We used Becks Depression Inventory (BDI) for depression screening, the questionnaires Fatigue Severity Scale (FSS) for fatigue and Short-Form-36 (SF36) for quality of life (QoL) evaluation and Consortium to establish a registry for Alzheimer's disease (CERAD-PLUS) as neuropsychological test battery.Results52 PLWH (47 males) and 28 non-infected controls (23 males) with a median age of 52 years (24–78 years) and 51 years (22–79) were analyzed. WTV correlated significantly with age (p < 0.01) but showed no significantly difference in PLWH (median = 3.4 mm) compared to healthy controls (median = 2.8 mm) (p = 0.085). PLWH had both significantly higher BDI-Scores (p = 0.005) and FSS-Scores (p = 0.012). Controls reported higher QoL (SF-36) with significant differences in most items. However, the overall cognitive performance (CERAD total score) showed no significant difference. The WTV of all subjects correlated with neurocognitive performance measured as CERAD total score (p = 0.009) and trail making tests A (p < 0.001) and B (p = 0.018). There was no correlation between the scores of BDI, FSS, SF-36, and CERAD-PLUS items and WTV.ConclusionWTV is considered as a predictor of cognitive deficits in neurodegenerative diseases. Nevertheless, we found no significant difference in WTV or overall cognitive performance between PLWH and controls. PLWH suffer more often from depression and fatigue and report reduced QoL when compared to healthy controls.

show abstract

Early Onset Alzheimer Type Dementia More Rapidly Deteriorates than Late Onset Type: A Follow‐up Study on MMSE Scores in Japanese Patients

et al. 2001

View full text Add to dashboard Cite

Examindon(MMSE), latent growth curve modelBackground: Cognitive function in patients with Alzheimer type dementia (ATD) changes over time, and the rate of progression varies according to reports. An aim of the study is to examine the rate of progression in patients with ATD by the onset of the disease. Methods: Forty patients with early onset dementia at the age of 65 or less and 99 patients with late onset dementia at the age of more than 65 years in whom Mini-Mental State Examination (MMSE) scores could be followed up for at least 12 months were enrolled and examined retrospectively for changes in MMSE scores over time. Results: It was demonstrated that the rate of decrease in MMSE scores was significantly higher in Alzheimer disease (AD) than in senile dementia of Alzheimer type (SDAT) and that the decrease in MMSE scores was significantly slower in patients with higher initial scores. Conclusion: ATD patients are likely to be classified into AD or SDAT for evaluation of decreased cognitive function. Initial MMSE score and the subtype according to age at onset are important predictors for the progression of intellectual impairment in ATD patients.

show abstract

Differences in Ventricle Dilation and Clinical Findings between the Early- and Late-Onset Subtypes of Alzheimer's Dementia.

Abstract: Attempts to vanquish Alzheimer's disease intensity, take new paths.

Cited by 3 publications

References 9 publications

First magenetic resonance imaging studies on aluminium maltolate‐treated aged New Zealand rabbits: an Alzheimer's animal model

First magenetic resonance imaging studies on aluminium maltolate‐treated aged New Zealand rabbits: an Alzheimer's animal model

Fewer neurocognitive deficits and less brain atrophy by third ventricle measurement in PLWH treated with modern ART: A prospective analysis

Early Onset Alzheimer Type Dementia More Rapidly Deteriorates than Late Onset Type: A Follow‐up Study on MMSE Scores in Japanese Patients

Contact Info

Product

Resources

About